Report Buyer, the online destination for business intelligence for major industry sectors, has now added a new report on the improving Antibiotics market. Anti-Infectives, Vol II: Antibacterials, forecasts a steady recovery and growth to more than $25 billion by 2011.

The global market for antibacterial pharmaceuticals has suffered from a major shift in sales from brand products to generics, causing revenues to drop. However, new products should generate significant sales and fuel recovery and growth in the market.

The cephalosporin antibiotic market in particular has fallen victim to increased generic competition and declining sales due to patent expirations of top brand products. Rocephin is a prime example of increased generic pressure as the product was once the leading cephalosporin antibiotic product on the market with more than $1 billion in annual sales.

There has been a call to increase the incentives that will reinvigorate industry research and development of new antibiotics, in addition to investing in programs that help limit the impact of antibiotic resistance. As a result, pharmaceutical companies are taking a second look at new antibacterial compounds after having been complacent for the last 20 years.

The report focuses on seven general segments of antibacterial treatment: cephalosporins, macrolides, penicillins, quinolones, sulfonamides, tetracyclines, and other miscellaneous antibiotics.

This report provides a comprehensive market overview of the significant trend shift occurring in the antibacterials market since the last edition in 2005. It covers both currently marketed and late stage development antibacterials. It also includes market size and forecasts, issues and trends affecting the industry, data on worldwide bacterial infections by type, and competitive analysis of leading providers.

Report Buyer product ID: KAL00015